# Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study

> **NCT05128617** · — · COMPLETED · sponsor: **Institut de cancérologie Strasbourg Europe** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicin-cyclophosphamide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05128617
- **Lead sponsor:** Institut de cancérologie Strasbourg Europe
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-04
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05128617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05128617, "Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05128617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*